Chicago Partner Susan Brice co-authored a multipart article in the Intellectual Property &Technology Law Journal exploring how genetic and epigenetic biomarkers of cause and effect can be used to help defend toxic tort cases. “Toxic tort cases generally involve claims that an individual was harmed as a consequence of exposure to a chemical(s) (including a medication). These cases can be particularly difficult to litigate because of the challenges presented by demonstrating or disproving causation,” Brice wrote. “By permitting the demonstration of alternative causation or the absence of a known cause and effect genetic pathway, genetics and epigenetics are quickly becoming a powerful tool in toxic tort litigation.” Click here to read the first part, originally printed in the September issue of the IPT Journal. Brice authored the series with Dr. Whitney V. Christian, a senior toxicologist at Medtronic who focuses on genetics, toxicology and gene-environment interactions and their contribution to the development of human disease.

Related Practices